Amycretin
GLP-1 + amylin (unimolecular) · s.c. / oral · Novo Nordisk
Summary
- Also known as
- zenagamtide
- Mechanism
- GLP-1 + amylin (unimolecular)
- Route
- s.c. / oral
- Company
- Novo Nordisk
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 (AMAZE) started verify
- Next milestone
- Phase 3 of the oral form
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 (AMAZE) ongoing | |
| T2D | 2 phase 3 ongoing | Phase 2 positive (Lancet 2026); phase 3 ongoing | Phase 2 s.c. in T2D |
| CV outcomes | 2 phase 3 ongoing | Phase 3 ongoing | |
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amycretin oral phase 1 | oral amycretin 50 mg | obesity | 12 | 144 | — | —−10.4 % vs −1.2 % estimand not specified | −0.2 vs +0.0 | — | — | 31.0 vs 8.0 | 38.0 vs 0.0 | 0.0 vs 0.0 | — | verified |
| Amycretin s.c. phase 1b/2a | amycretin 60 mg | obesity | 36 | 125 | −24.3 % vs −1.1 % Δ −23.2 pp | — | −0.6 vs −0.1 | — | — | 82.0 vs 60.0 | 47.0 vs 60.0 | 0.0 vs 0.0 | — | verified |
| Amycretin s.c. phase 1b/2a | amycretin 20 mg | obesity | 36 | 125 | −22.0 % vs +2.0 % Δ −24.0 pp | — | −0.3 vs −0.1 | — | — | 79.0 vs 40.0 | 53.0 vs 20.0 | 3.0 vs 0.0 | — | verified |
| Zenagamtide s.c. phase 2 (T2D) | zenagamtide 10 mg weekly | t2d | 36 | 38 | −12.9 % vs −2.1 % Δ −10.8 pp | — | −1.4 vs −0.1 | 21.0 vs 6.0 | — | 26.0 vs 14.0 | 11.0 vs 6.0 | 13.0 vs 8.0 | −9.4 vs −3.5 | verified |
| Zenagamtide s.c. phase 2 (T2D) | zenagamtide 20 mg weekly | t2d | 36 | 38 | −13.1 % vs −2.1 % Δ −11.0 pp | — | −1.6 vs −0.1 | 34.0 vs 6.0 | 45.0 vs 14.0 | 50.0 vs 14.0 | 24.0 vs 6.0 | 8.0 vs 8.0 | −7.2 vs −3.5 | verified |
| Zenagamtide s.c. phase 2 (T2D) | zenagamtide 40 mg weekly | t2d | 36 | 38 | −14.6 % vs −2.1 % Δ −12.5 pp | — | −1.7 vs −0.1 | 34.0 vs 6.0 | 45.0 vs 14.0 | 37.0 vs 14.0 | 29.0 vs 6.0 | 3.0 vs 8.0 | −10.6 vs −3.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- amycretin 20 mg: The paper reports «events leading to withdrawal» (21 % vs 20 % placebo, part C), not discontinuation of the study drug.
- oral amycretin 50 mg: Part C1, 50 mg once daily (n=16 vs 12 placebo); observed mean change, estimand not stated.
Verbatim quotes from the source (37)
- amycretin 60 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
- amycretin 60 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
- amycretin 60 mg · sae · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Yes 0 0 1 (3%), 1 0 0 0 0 0
- amycretin 60 mg · hba1c · Table 3, Glycated haemoglobin rows
Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2)
- amycretin 20 mg · weight_eff · Table 3
Estimated change from baseline to EOT –24·3% (1·9) –1·1% (3·0) –22·0% (1·0) 1·9% (2·5) –16·2% (1·1) 2·3% (1·8) –9·7% (1·3) 2·0% (2·4)
- amycretin 20 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
- amycretin 20 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
- amycretin 20 mg · sae · Table 2
Yes 0 0 1 (3%), 1 0 0 0 0 0
- amycretin 20 mg · hba1c · Table 3
Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2) –0·3% (0·1) –0·1% (0·1) –0·2% (0·1) 0·1% (0·1) –0·2% (0·1) –0·1% (0·1)
- oral amycretin 50 mg · nausea · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Nausea 5 (31%) 6 12 (75%) 14 15 (94%) 18 1 (8%)
- oral amycretin 50 mg · sae · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Serious adverse event Yes 0 0 0 0 1 (6%) 1 0 0
- oral amycretin 50 mg · vomiting · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
Vomiting 6 (38%) 7 9 (56%) 11 10 (63%) 11 0 0
- oral amycretin 50 mg · hba1c · Table 3
HbA1c, % Screening, mean (SD) 5·2 (0·4) 5·2 (0·3) 5·4 (0·4) 5·3 (0·4) Day 85, mean (SD) 5·0 (0·3) 5·0 (0·2) 5·1 (0·2) 5·3 (0·3) Change from day 1 to day 85, mean (SD) –0·2 (0·2) –0·3 (0·3) –0·3 (0·2) 0·0 (0·2) ETD (95% C
- oral amycretin 50 mg · weight_unsp · Table 3 (exploratory PD endpoints part C/D), column 1 = Amyc
Amycretin 50 mg (n=16) Amycretin 2 × 50 mg (n=16) Amycretin 2 × 25 mg (n=16) Placebo* (n=12) Bodyweight, % Change from day 1 to day 85, mean (SD) –10·4 (4·6) –13·1 (4·8) –12·2 (4·5) –1·2 (2·4) Minimum change –2·2 –6·2 –4
- zenagamtide 10 mg weekly · weight_eff · Table 2, Bodyweight change, % row
−4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
- zenagamtide 10 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 10 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 10 mg weekly · vomiting · Table 3
Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
- zenagamtide 10 mg weekly · sae · Results, adverse events paragraph; Table 3
five (13%) in the 10 mg group
- zenagamtide 10 mg weekly · hba1c · Table 2
Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
- zenagamtide 10 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
- zenagamtide 20 mg weekly · weight_eff · Table 2, Bodyweight change, % row
−4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
- zenagamtide 20 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 20 mg weekly · disc_any · Results, paragraph 2
17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
- zenagamtide 20 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 20 mg weekly · vomiting · Table 3
Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
- zenagamtide 20 mg weekly · sae · Results, adverse events paragraph; Table 3
three (8%) in the 20 mg group
- zenagamtide 20 mg weekly · hba1c · Table 2
Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
- zenagamtide 20 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
- zenagamtide 40 mg weekly · weight_eff · Results, paragraph 7; Table 2
to −14·6% with zenagamtide 40 mg (−12·5% [−16·79 to −8·21]; p<0·0001), compared with −2·1% with placebo
- zenagamtide 40 mg weekly · ae_dc · Table 3
Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
- zenagamtide 40 mg weekly · disc_any · Results, paragraph 2
17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
- zenagamtide 40 mg weekly · nausea · Table 3
Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
- zenagamtide 40 mg weekly · vomiting · Results, adverse events paragraph; Table 3
vomiting in one (3%) of 38 participants in the 0·4 mg group and 11 (29%) of 38 participants in the 40 mg group
- zenagamtide 40 mg weekly · sae · Results, adverse events paragraph; Table 3
one (3%) in the 40 mg group
- zenagamtide 40 mg weekly · hba1c · Results, paragraph 3; Table 2
to −1·7% with zenagamtide 40 mg (−1·56% [−2·05 to −1·07]; p<0·0001; table 2)
- zenagamtide 40 mg weekly · sbp · Table 2, SBP row
Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
Registered trials (19)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| AMAZE 13 AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight | Obesity | Phase 3 | not yet recruiting | 2027-01 → 2029-01 | 400 | not yet recruiting | NCT07668401 |
| AMBITION 1 A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | T2D | Phase 3 | not yet recruiting | 2026-11 → 2028-06 | 200 | not yet recruiting | NCT07931495 |
| AMBITION 2 A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both | CKD | Phase 3 | not yet recruiting | 2026-11 → 2028-07 | 450 | not yet recruiting | NCT07931547 |
| AMBITION 3 AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both | T2D | Phase 3 | not yet recruiting | 2026-11 → 2028-07 | 1200 | not yet recruiting | NCT07931573 |
| AMBITION4 A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both | T2D | Phase 3 | not yet recruiting | 2026-11 → 2028-07 | 1060 | not yet recruiting | NCT07931599 |
| AMBIENCE A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity | CV outcomes | Phase 3 | not yet recruiting | 2026-10 → 2030-09 | 8500 | not yet recruiting | NCT07861100 |
| AMAZE 7 A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Obesity | Phase 3 | recruiting | 2026-09 → 2028-10 | 650 | recruiting | NCT07668414 |
| AMAZE 10 AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight | Obesity | Phase 3 | recruiting | 2026-09 → 2029-02 | 400 | recruiting | NCT07822061 |
| AMAZE 9 AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight | Obesity | Phase 3 | recruiting | 2026-08 → 2028-06 | 950 | recruiting | NCT07720271 |
| AMBITION 7 AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | T2D | Phase 3 | recruiting | 2026-08 → 2028-07 | 1778 | recruiting | NCT07797335 |
| AMAZE 8 AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Obesity | Phase 3 | active not recruiting | 2026-05 → 2028-12 | 985 | active not recruiting | NCT07400107 |
| HF-POLARIS A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | CV outcomes | Phase 3 | recruiting | 2026-05 → 2029-07 | 5610 | recruiting | NCT07567001 |
| AMAZE 3 AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Sleep apnoea | Phase 3 | recruiting | 2026-05 → 2028-07 | 300 | recruiting | NCT07571005 |
| AMAZE 4 AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea | Sleep apnoea | Phase 3 | recruiting | 2026-05 → 2028-06 | 300 | recruiting | NCT07571109 |
| AMAZE 5 A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain | Knee OA | Phase 3 | recruiting | 2026-04 → 2028-08 | 400 | recruiting | NCT07481630 |
| AMAZE 12 AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss | Obesity | Phase 3 | active not recruiting | 2026-04 → 2028-06 | 606 | active not recruiting | NCT07503210 |
| AMAZE 6 AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain | Knee OA | Phase 3 | recruiting | 2026-04 → 2028-08 | 400 | recruiting | NCT07509307 |
| AMAZE 2 AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Obesity | Phase 3 | active not recruiting | 2026-04 → 2028-08 | 638 | active not recruiting | NCT07533175 |
| AMAZE 1 AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Obesity | Phase 3 | recruiting | 2026-02 → 2029-06 | 1150 | recruiting | NCT07339423 |
Primary sources
- Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10499):149-162. PMID: 40550231.
- Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, Kirkeby K, Kruse T, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10499):135-148. PMID: 40550229.
- Mora P, Aroda VR, Asong M, Blüher M, Heftdal LD, Carlander AF, et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026;408(10555):621-635. PMID: 42532080.
How to cite this page
Cite the primary publication for any single result; every value above links to it.